JP2025508943A5 - - Google Patents

Info

Publication number
JP2025508943A5
JP2025508943A5 JP2024551973A JP2024551973A JP2025508943A5 JP 2025508943 A5 JP2025508943 A5 JP 2025508943A5 JP 2024551973 A JP2024551973 A JP 2024551973A JP 2024551973 A JP2024551973 A JP 2024551973A JP 2025508943 A5 JP2025508943 A5 JP 2025508943A5
Authority
JP
Japan
Prior art keywords
alternatively
alkyl
group
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024551973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508943A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/014293 external-priority patent/WO2023167938A1/en
Publication of JP2025508943A publication Critical patent/JP2025508943A/ja
Publication of JP2025508943A5 publication Critical patent/JP2025508943A5/ja
Pending legal-status Critical Current

Links

JP2024551973A 2022-03-02 2023-03-01 ウイルス感染症の治療のための化合物及び方法 Pending JP2025508943A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263315919P 2022-03-02 2022-03-02
US63/315,919 2022-03-02
US202263413748P 2022-10-06 2022-10-06
US63/413,748 2022-10-06
PCT/US2023/014293 WO2023167938A1 (en) 2022-03-02 2023-03-01 Compounds and methods for treatment of viral infections

Publications (2)

Publication Number Publication Date
JP2025508943A JP2025508943A (ja) 2025-04-10
JP2025508943A5 true JP2025508943A5 (https=) 2026-03-10

Family

ID=85772852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024551973A Pending JP2025508943A (ja) 2022-03-02 2023-03-01 ウイルス感染症の治療のための化合物及び方法

Country Status (8)

Country Link
US (1) US20230322813A1 (https=)
EP (1) EP4486746A1 (https=)
JP (1) JP2025508943A (https=)
KR (1) KR20240154646A (https=)
AU (1) AU2023227470A1 (https=)
CA (1) CA3243944A1 (https=)
TW (2) TWI878811B (https=)
WO (1) WO2023167938A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN119039322A (zh) * 2023-09-19 2024-11-29 广东晨康生物科技有限公司 一种环碳酸酯核苷化合物的盐、晶体及其制备方法和应用
CN119792537B (zh) * 2025-01-22 2025-10-21 常州大学 利巴韦林与pd-1抑制剂联合用药物组合物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
JP5030587B2 (ja) 2003-06-26 2012-09-19 バイオトロン・リミテッド 抗ウイルスアシルグアニジン化合物および方法
EP2826770B1 (en) 2005-06-24 2018-09-12 Biotron Limited Acylguanidine compounds with antiviral activity
US20100254942A1 (en) 2007-08-03 2010-10-07 Biotron Limited Hepatitis c antiviral compositions and methods
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
SI3043865T1 (sl) 2013-09-11 2021-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
EA201691261A1 (ru) 2014-01-30 2016-11-30 Ф. Хоффманн-Ля Рош Аг Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
AU2015226206B2 (en) 2014-03-07 2017-03-16 F. Hoffmann-La Roche Ag Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
KR20160148715A (ko) 2014-05-13 2016-12-26 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
BR112017002970B1 (pt) 2014-08-14 2023-04-11 F. Hoffmann-La Roche Ag Novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
AR103222A1 (es) 2014-12-23 2017-04-26 Hoffmann La Roche Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CN107108610B (zh) 2014-12-30 2019-06-04 豪夫迈·罗氏有限公司 用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
CN107109497A (zh) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
WO2016120186A1 (en) 2015-01-27 2016-08-04 F. Hoffmann-La Roche Ag Recombinant hbv cccdna, the method to generate thereof and the use thereof
HK1244281B (zh) 2015-02-11 2020-02-07 F. Hoffmann-La Roche Ag 治疗和预防乙型肝炎病毒感染的2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
WO2017184668A1 (en) * 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
SG11201907034PA (en) 2017-02-08 2019-08-27 Biotron Ltd Methods of treating influenza
JP2023512656A (ja) * 2020-01-27 2023-03-28 ギリアード サイエンシーズ, インコーポレイテッド SARS CoV-2感染を治療するための方法
TWI791193B (zh) * 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
CN112778310B (zh) * 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
IL300453A (en) * 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
KR102918401B1 (ko) * 2020-12-30 2026-01-26 서던 유니버시티 오브 사이언스 앤드 테크놀로지 코로나 바이러스 감염을 치료하기 위한 방법 및 변형된 뉴클레오사이드
US20240166680A1 (en) * 2021-04-15 2024-05-23 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Nucleoside analog and use thereof
CN114181258B (zh) * 2021-12-29 2023-10-13 南京师范大学 用于抗病毒治疗的核苷类化合物及用途
CN114437159B (zh) * 2022-04-11 2022-06-28 佛山市晨康生物科技有限公司 一种环状碳酸酯核苷类化合物及其应用

Similar Documents

Publication Publication Date Title
JP2025508943A5 (https=)
JP2025508942A5 (https=)
JP2023531524A5 (https=)
CN112778310B (zh) 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
JP2005533824A5 (https=)
JP2023540225A5 (https=)
JP2010539241A5 (https=)
JP2011521903A5 (https=)
HRP20240733T1 (hr) Spojevi i postupci za liječenje virusnih infekcija
ES2563477T3 (es) Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina
JP2023551174A5 (https=)
JP2011518835A5 (https=)
RU2011133741A (ru) Модифицированные 2'- и 3'-нуклеозиды и их применение для получения лекарственного средства для лечения инфекций flaviviridae
JP2015523365A5 (https=)
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
JP2022505597A5 (https=)
JP2013056886A5 (https=)
JP2006528700A5 (https=)
CA2490200A1 (en) 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
JP2017505314A5 (https=)
JPH11512083A (ja) C型肝炎の治療における1,3−オキサチオランヌクレオシドアナログ
JP2021521118A (ja) 肝硬変を伴うhcv感染患者の治療
RU2014113539A (ru) Тетрациклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний
JP2025096283A5 (https=)
JP2018512453A5 (https=)